RegWardenFDA facility compliance records
Recall

Class II — The Binding Site Group, Ltd.

Recalling firmTHE BINDING SITE, INC.
Registered facilityTHE BINDING SITE, INC. (the firm's only registered facility)
ClassificationClass II
StatusTerminated
ReasonThe product is not meeting the antigen excess protection claim of up to 760mg/L, as stated in the Instructions for Use.
ProductBinding Site Optilite Beta-2-Microglobulin Urine Kit, Ref LK043.L.OPT.A, IVD. The firm name on the label is The Binding Site Group Ltd., Birmingham, U.K. The Optilite Beta-2-Microglobulin (2M) Urine kit is intended for the quantitative in-vitro measurement of beta-2-microglobulin in urine using the Binding Site Optilite analyser to aid in the diagnosis of active rheumatoid arthritis and kidney disease. This test should be used in conjunction with other laboratory and clinical findings.
Quantity20 kits distributed to the U.S.
DistributionUS Distribution was made to CA. There was no foreign/military/government distribution.
Initiated2018-03-09
Classified2018-04-03
Terminated2020-06-22
Recall numberZ-1301-2018
InitiationVoluntary: Firm initiated

Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this recall record at FDA → (opens in a new tab)

Cite this record

RegWarden. “Class II recall — The Binding Site Group, Ltd. (Z-1301-2018).” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/recall/79499/

Not open yet

Alerts for THE BINDING SITE, INC.

Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.

Planned

Want a one-page facility brief?

A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.